CandlesenseCandlesense
MRK•benzinga•

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types

Summary

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 17, 2025 by benzinga

← Back to MRK News
    Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types | MRK Stock News | Candlesense